 BASKING RIDGE, N.J., Jan. 21, 2021 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise 25.0 million through the issuance of an aggregate 12,500,000 shares of its common stock or common stock equivalents in lieu thereof and warrants to purchase up to an aggregate of 6,250,000 shares of common stock, at a purchase price of 2.00 per share of common stock or common stock equivalent in lieu thereof and associated warrant in a private placement priced at-the-market under Nasdaq rules. The closing of the private placement is expected to occur on or about January 25, 2021, subject to satisfaction of customary closing conditions. 